OneSource Specialty Pharma LimitedNSE: ONESOURCE

Press Release May 13 2026

· Issued by OneSource Specialty Pharma Limited

Filed with NSE · · 26 pages · English

Summary by 6ix AI

The company reaffirmed its guidance for future revenue and EBITDA margins, indicating confidence in continued growth supported by recent approvals and market expansions. Overall, the results reflect a recovery from previous challenges, with a focus on expanding capabilities and maintaining compliance across its operations.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated May 13, 2026, titled "OneSource Announces FY26 Results with Strong Q4 Performance;Reaffirms FY28 Guidance".

OneSource Specialty Pharma Limited on 6ix

In the deck

Earlier from OneSource Specialty Pharma

Later from OneSource Specialty Pharma

All OneSource Specialty Pharma news releases